Various recombinant vaccines manufacturers have allotted a new capital framework to help shape their strategic priorities. Improving pipelines for new pharmaceutical products is the main priority for recombinant vaccines manufacturers and has the potential for a marked improvement in their performance. Manufacturers are investing behind their key recombinant vaccines, which is expected to drive growth the growth of the market in the coming years.
Increasing government initiatives for using recombinant vaccines in North, Europe, Latin America, and Asia pacific region is fueling the growth of the Recombinant Vaccines market. The growing demand for sustainable & optimized healthcare has increased the demand for Recombinant Vaccines. Moreover, ease of application of Recombinant Vaccines and the availability of Recombinant Vaccines through traditional supply chains are leading to increasing adoption rates of Recombinant Vaccines among distribution channel.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Recombinant vaccines haven’t infiltrated healthcare settings, especially in Middle East, Africa, and APEJ. Large number of patients are not aware about recombinant vaccines in not only the developing economies, but also a considerable portion of developed economies. Market players are yet to market recombinant vaccines efficiently in order to exploit their full market potential.
Awareness, advertisement, and proper marketing and are expected to help grab lucrative revenue opportunities over the forecast period. Although the adoption rate of recombinant vaccines is moderate in hospital settings globally, it poses a great market potential for manufacturers.
Recombinant vaccines are projected to gain popularity as they provide great benefits for the patient, reduced side effect profiles, and reduced costs associated with therapeutic intervention as the hospital expenditure is reduced using recombinant vaccines.
Principal Consultant
The recombinant vaccines market is mainly dominated by global manufactures. These manufacturers of recombinant vaccines are competing based on adoption of their respective recombinant vaccines. The increasing awareness about recombinant vaccines and a growing demand for optimized & sustainable healthcare has increased the revenue opportunity for the global manufacturers.
Companies like GlaxoSmithKline plc, and Merck & Co Inc, hold more than 80% revenue share in the global recombinant vaccines market. Launching novel products is one of the main focus of key market players. Also, companies operating in the recombinant vaccines market are collaborating with retailers and local distributors in order to increase the penetration of their respective recombinant vaccines.
According to the discussions held with key opinion leaders in the recombinant vaccines market, a substantial growth has been witnessed in Asia Pacific market for recombinant vaccines market. Manufacturers in China & APEC are estimated to grow significantly in the recombinant vaccines market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Recombinant vaccines face stiff competition from parallel product categories such as live attenuated vaccines. These vaccines offer broad spectrum immunity, and also reduce the number of dosages required. Attenuated vaccines are also known to be effective in stimulating both humoral as well as cellular immune responses. However, live attenuated vaccines in recombinant form could lead to disease transmission in immune-compromised hosts, which at times deter usage.
The company’s report titled “Recombinant Vaccines Market” provides detailed information about the growth parameters of the companies operating in the recombinant vaccines market. It includes detailed assessment of the competitive environment in the recombinant vaccines market.
The market study provides comprehensive data on each stakeholder in the recombinant vaccines market, including GlaxoSmithKline Biologicals, MERCK & CO., INC, Dynavax Technologies Corporation, Sanofi Pasteur, Bharat Biotech, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., LG Chem, Sinovac Biotech Ltd, Pfizer, C.H. Boehringer Sohn AG & Co.KG. The report provides readers with all-encompassing data on each recombinant vaccine manufacturer’s revenue shares, winning strategies, and latest information on key strategies in the recombinant vaccines market.
Subunit recombinant vaccines are derived from killed vaccines. Their synthesis is non-toxic in nature. They contain highly immunogenic microbial antigens and are made with the help of recombinant DNA technology. Worth noting that the antigen component of subunit vaccines is covalently linked to a carrier, mostly a protein.
Attenuated recombinant vaccines are designed to specifically attenuate the microbe. Advantage of this type is mutant lesion in the microbe is specific, rather than randomly placed. These vaccines can be produced rapidly to meet sudden demands. Also it is easy to track the surveillance of these vaccines to revert back to virulence.
The study on the recombinant vaccines market was recently published by the company, which provides comprehensive information about the most important market dynamics that prove instrumental in the growth of the recombinant vaccines market during 2018-2026. Companies in the recombinant vaccines market can find the most accurate quantitative and qualitative information about the growth parameters of the other recombinant vaccine manufacturers, which can help them develop data-driven business strategies in the coming future.
Readers can find detailed information about the important positive and negative factors affecting the recombinant vaccines market during the forecast period. Additionally, the report also contains valuable information that can provide recombinant vaccines manufacturers with answers to critical questions, such as
The process of market research followed by the company commences with extensive secondary research of the recombinant vaccines market. We have obtained industry-validated, historic, and current data about the demand for recombinant vaccines across the globe. Comprehensive secondary research was followed by extensive and in-depth primary research, where detailed information about the recombinant vaccines market was obtained in terms of value (US$ Million).
Based on thorough secondary and primary research of the growth parameters of the recombinant vaccines market, we have come up with the most precise forecast on how the recombinant vaccines market will grow during the forecast period.
The report on the recombinant vaccines market provides salient information on market players. The recombinant vaccines market is segmented by region, product type, application, and distribution channel, to analyze segment-wise growth of the recombinant vaccines market. Based on regions, the recombinant vaccines market is segmented into seven regions – North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, and the Middle East & Africa (MEA).
The recombinant vaccines market by product type is segmented intosubunit recombinant vaccines, attenuated recombinant vaccines, vector recombinant vaccines. By application, the recombinant vaccines market is segregated into human, and veterinary recombinant vaccines. By distribution channel, the recombinant vaccines market is segregated into hospitals, private clinics & dispensaries, retail pharmacies & others.
The recombinant vaccines market competition is consolidated in nature with leading players accounting for 80% of the total share
Stiff competition from alternate products is likely to limit the otherwise strong growth potential.
As per the demand analysis, the recombinant vaccines market is likely to record a CAGR of 8.75% through 2032.
The recombinant vaccines market size grew to US$ 42.08 billion in 2022.
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
2.3. Exclusion and Inclusion
2.4. Target Market Analysis (US$ Mn), 2018
2.4.1. Global Filtration Market
2.4.2. Global Membrane Market
3. Market Dynamics
3.1. Macro-Economic Factors
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Trends
4. Key Inclusions
4.1. Pricing Analysis
4.2. Pipeline Analysis
5. North America Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028
5.1. Introduction
5.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2017
5.2.1. U.S.
5.2.2. Canada
5.3. Market Value (US$ Mn) Forecast By Country, 2018-2028
5.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017
5.4.1. Subunit Recombinant Vaccines
5.4.2. Attenuated Recombinant Vaccines
5.4.3. Vector Recombinant Vaccines
5.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028
5.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017
5.6.1. Human
5.6.2. Veterinary
5.7. Market Value(US$ Mn) Forecast By Application, 2018-2028
5.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
5.8.1. Hospitals
5.8.2. Private Clinics & Dispensaries
5.8.3. Retail Pharmacies
5.8.4. Others
5.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028
5.10. Market Attractiveness Analysis
5.10.1. By Country
5.10.2. By Product Type
5.10.3. By Application
5.10.4. By Distribution Channel
5.11. Drivers and Restraints: Impact Analysis
5.12. Key Market Participants – Intensity Mapping
6. Latin America Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028
6.1. Introduction
6.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017
6.2.1. Brazil
6.2.2. Mexico
6.2.3. Argentina
6.2.4. Rest of Latin America
6.3. Market Value(US$ Mn) Forecast By Country, 2018-2028
6.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017
6.4.1. Subunit Recombinant Vaccines
6.4.2. Attenuated Recombinant Vaccines
6.4.3. Vector Recombinant Vaccines
6.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028
6.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017
6.6.1. Human
6.6.2. Veterinary
6.7. Market Value(US$ Mn) Forecast By Application, 2018-2028
6.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
6.8.1. Hospitals
6.8.2. Private Clinics & Dispensaries
6.8.3. Retail Pharmacies
6.8.4. Others
6.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028
6.10. Market Attractiveness Analysis
6.10.1. By Country
6.10.2. By Product Type
6.10.3. By Application
6.10.4. By Distribution Channel
6.11. Drivers and Restraints: Impact Analysis
6.12. Key Market Participants – Intensity Mapping
7. Western Europe Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028
7.1. Introduction
7.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017
7.2.1. Germany
7.2.2. U.K
7.2.3. France
7.2.4. Italy
7.2.5. Spain
7.2.6. Nordics
7.2.7. Benelux
7.2.8. Rest of Western Europe
7.3. Market Value(US$ Mn) Forecast By Country, 2018-2028
7.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017
7.4.1. Subunit Recombinant Vaccines
7.4.2. Attenuated Recombinant Vaccines
7.4.3. Vector Recombinant Vaccines
7.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028
7.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017
7.6.1. Human
7.6.2. Veterinary
7.7. Market Value(US$ Mn) Forecast By Application, 2018-2028
7.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
7.8.1. Hospitals
7.8.2. Private Clinics & Dispensaries
7.8.3. Retail Pharmacies
7.8.4. Others
7.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028
7.10. Market Attractiveness Analysis
7.10.1. By Country
7.10.2. By Product Type
7.10.3. By Application
7.10.4. By Distribution Channel
7.11. Drivers and Restraints: Impact Analysis
7.12. Key Market Participants – Intensity Mapping
8. Eastern Europe Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028
8.1. Introduction
8.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017
8.2.1. Russia
8.2.2. Poland
8.2.3. Rest of Eastern Europe
8.3. Market Value(US$ Mn) Forecast By Country, 2018-2028
8.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017
8.4.1. Subunit Recombinant Vaccines
8.4.2. Attenuated Recombinant Vaccines
8.4.3. Vector Recombinant Vaccines
8.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028
8.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017
8.6.1. Human
8.6.2. Veterinary
8.7. Market Value(US$ Mn) Forecast By Application, 2018-2028
8.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
8.8.1. Hospitals
8.8.2. Private Clinics & Dispensaries
8.8.3. Retail Pharmacies
8.8.4. Others
8.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028
8.10. Market Attractiveness Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.10.4. By Distribution Channel
8.11. Drivers and Restraints: Impact Analysis
8.12. Key Market Participants – Intensity Mapping
9. Asia Pacific Excluding China & Japan Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028
9.1. Introduction
9.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017
9.2.1. India
9.2.2. China
9.2.3. Australia and New Zealand
9.2.4. ASEAN
9.2.5. Rest of APECJ
9.3. Market Value(US$ Mn) Forecast By Country, 2018-2028
9.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017
9.4.1. Subunit Recombinant Vaccines
9.4.2. Attenuated Recombinant Vaccines
9.4.3. Vector Recombinant Vaccines
9.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028
9.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017
9.6.1. Human
9.6.2. Veterinary
9.7. Market Value(US$ Mn) Forecast By Application, 2018-2028
9.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
9.8.1. Hospitals
9.8.2. Private Clinics & Dispensaries
9.8.3. Retail Pharmacies
9.8.4. Others
9.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028
9.10. Market Attractiveness Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Distribution Channel
9.11. Drivers and Restraints: Impact Analysis
9.12. Key Market Participants – Intensity Mapping
10. Japan Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028
10.1. Introduction
10.2. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017
10.2.1. Subunit Recombinant Vaccines
10.2.2. Attenuated Recombinant Vaccines
10.2.3. Vector Recombinant Vaccines
10.3. Market Value (US$ Mn) Forecast By Product Type, 2018-2028
10.4. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017
10.4.1. Human
10.4.2. Veterinary
10.5. Market Value(US$ Mn) Forecast By Application, 2018-2028
10.6. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
10.6.1. Hospitals
10.6.2. Private Clinics & Dispensaries
10.6.3. Retail Pharmacies
10.6.4. Others
10.7. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028
10.8. Market Attractiveness Analysis
10.8.1. By Product Type
10.8.2. By Application
10.8.3. By Distribution Channel
10.9. Drivers and Restraints: Impact Analysis
10.10. Key Market Participants – Intensity Mapping
11. Middle East and Africa Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028
11.1. Introduction
11.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017
11.2.1. GCC Countries
11.2.2. South Africa
11.2.3. Rest of Middle East and Africa
11.3. Market Value(US$ Mn) Forecast By Country, 2018-2028
11.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017
11.4.1. Subunit Recombinant Vaccines
11.4.2. Attenuated Recombinant Vaccines
11.4.3. Vector Recombinant Vaccines
11.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028
11.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017
11.6.1. Human
11.6.2. Veterinary
11.7. Market Value(US$ Mn) Forecast By Application, 2018-2028
11.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
11.8.1. Human
11.8.2. Veterinary
11.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028
11.10. Market Attractiveness Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Distribution Channel
11.11. Drivers and Restraints: Impact Analysis
11.12. Key Market Participants – Intensity Mapping
12. Market Structure Analysis
12.1. Market Structure by Tier
12.2. Market Share Analysis (2017)
13. Competition Analysis
13.1. Competition Dashboard
13.2. Company Profiles
13.2.1. GlaxoSmithKline Plc
13.2.1.1. Overview of Division & Business Unit
13.2.1.2. Analyst Commentary
13.2.1.3. Key Developments
13.2.1.4. Key Financials
13.2.2. MERCK & CO., INC
13.2.3. Dynavax Technologies Corporation
13.2.4. Sanofi Pasteur
13.2.5. Bharat Biotech
13.2.6. Indian Immunologicals Limited
13.2.7. Serum Institute of India Pvt. Ltd.
13.2.8. LG Chem
13.2.9. Sinovac Biotech Ltd
13.2.10. Pfizer
13.2.11. C.H. Boehringer Sohn AG & Co.KG
14. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028 By Region
14.1. Introduction / Key Findings
14.2. Historical Market Value(US$ Mn) Analysis By Region
14.2.1. North America
14.2.2. Latin America
14.2.3. Western Europe
14.2.4. Eastern Europe
14.2.5. Asia Pacific Excluding Japan China
14.2.6. Japan
14.2.7. Middle East and Africa
14.3. Market Value(US$ Mn) Forecast By Region
14.4. Market Attractiveness Analysis By Region
15. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028, By Product Type
15.1. Introduction/Key Finding
15.2. Historical Market Value(US$ Mn) Analysis By Product Type, 2013-2017
15.2.1. Subunit Recombinant Vaccines
15.2.2. Attenuated Recombinant Vaccines
15.2.3. Vector Recombinant Vaccines
15.3. Market Value(US$ Mn) Forecast By Product Type, 2018-2028
15.4. Market Attractiveness Analysis By Product Type
16. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028, By Application
16.1. Introduction/Key Finding
16.2. Historical Market Value(US$ Mn) Analysis By Application, 2013-2017
16.2.1. Human
16.2.2. Veterinary
16.3. Market Value(US$ Mn) Forecast By Application, 2018-2028
16.4. Market Attractiveness Analysis By Application
17. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel
17.1. Introduction/Key Finding
17.2. Historical Market Value(US$ Mn) Analysis By Application, 2013-2017
17.2.1. Hospitals
17.2.2. Private Clinics & Dispensaries
17.2.3. Retail Pharmacies
17.2.4. Others
17.3. Market Value(US$ Mn) Forecast By Application, 2018-2028
17.4. Market Attractiveness Analysis By Application
18. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028
18.1. Market Value Share Analysis By All Segment
18.2. Y-o-Y Growth Analysis By All Segment
18.3. Absolute $ Opportunity
19. Assumptions and Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Recombinant Vaccines Market
